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Abstract: Metal dyshomeostasis is central to a number of disorders 
that result from, inter alia, oxidative stress protein misfolding, and 
cholesterol dyshomeostasis. In this respect, metal deficiencies are 
usually readily corrected by treatment with supplements, whereas 
metal overload can be overcome by the use of metal-selective 
chelation therapy. Deferasirox, 4-[(3Z,5E)-3,5-bis(6-oxo-1-cyclohexa-
2,4-dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid, Exjade, or  
ICL670, is used clinically to treat hemosiderosis (iron overload), which 
often results from multiple blood transfusions. Cyclodextrins are cyclic 
glucose units that are extensively used in the pharmaceutical industry 
as formulating agents as well as for encapsulating hydrophobic 
molecules such as in the treatment of Niemann Pick C or for 
hypervitaminosis. We have conjugated deferasirox, via an amide 
coupling reaction, to both 6A-amino-6A-deoxy-β-cyclodextrin and 3A-
amino-3A-deoxy-2A(S),3A(S)-β-cyclodextrin, at the upper and lower 
rim respectively creating hybrid molecules with dual properties, 
capable of both metal chelation and cholesterol encapsulation. Our 
findings emphasize the importance of the conjugation of β-
cyclodextrin with deferasirox to significantly improve the biological 
properties and reduce the cytotoxicity of this drug. 
Introduction 
Chelation therapy is considered as one treatment option to reduce 
the toxic effects of metal ions in humans. Besides the removal of 
toxic foreign metals, chelation therapy is also used to reduce 
levels of essential metals in cases of copper or iron overload 
disorders as in Wilson’s disease, primary and secondary 
hemochromatosis.1,2 Moreover, the use of chelating agents has 
also been proposed for neurodegenerative disorders related to 
oxidative stress, disruption of metal, and cholesterol 
homeostasis.3,4 Deferasirox (3, Exjade, ICL670) is an orally 
available, once-daily, clinical iron chelator commonly used to treat 
hemosiderosis, after multiple transfusions, non–transfusion-
dependent thalassemia (NTDT), sickle cell anemia and 
myelodysplastic syndromes (MDS).5 The development of 
chelating agents for iron, which, nowadays includes desferal, 
deferiprone and deferasirox, is challenging given that all present 
different drawbacks.6-8 In particular, nephrotoxicity is one of the 
most frequent adverse effects of iron chelator treatment.9  
In an attempt to overcome these limitations, different strategies 
have been proposed, viz. covalent modification of the deferasirox 
scaffold10 and non-covalent inclusion in a cyclodextrin (CyD) 
cavity.11 
We have previously conjugated metal chelators such as 
deferiprone and clioquinol with β-cyclodextrin (CyD).12,13 Studies 
on these conjugates have indicated that the CyD conjugation 
improves some features of chelators and makes them 
multifunctional.14,15 CyDs have been studied as artificial 
chaperones and antiaggregant agents.16,17 Methyl-β-CyD has 
been reported to reduce α-synuclein (αSyn) accumulation, a 
protein implicated in Parkinson’s disease (PD).18 Also, some 
authors have reported that dietary CyDs can influence 
metallothionein mRNA levels in rats.19 This ability may cooperate 
with the chelating ability of the moiety since metallothioneins play 
a prominent role in metal homeostasis. Finally, the CyD cavity can 
be available to include exogenous drugs as well as endogenous 
cholesterol and lipids that are also involved in neurodegenerative 
diseases. Several studies have investigated the effect of 
cholesterol-reducing agents such as CyDs on neurodegenerative 
pathologies.20,21 Trappsol TM, hydroxypropyl-beta-cyclodextrin 
(HP-B-CD), is currently under clinical trials in Niemann–Pick type 
C (NPC), a lysosomal lipid storage disorder characterized by an 
accumulation of lipids such as cholesterol. This context has 
inspired us to synthesize and investigate new conjugates of CyD 
with deferasirox. Herein, we report the synthesis and 
characterization of 4-[3,5bis(2-hydroxyphenyl)-1H-1,2,4triazol-1-
yl]-N-[6A-amino-6A-deoxy-β-cyclodextrin]-benzamide (1, Figure 
1) and 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-N-[3A-
deoxy-3A-amino-β-cyclodextrin]-benzamide (2, Figure 1) since 3- 
and 6-monofunctionalized β-cyclodextrin may have significant 
different chemical and biological properties owing to their different 
structures. Given the multifactorial nature of neurodegenerative 
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disorders, we evaluated the ability of the new CyD conjugates to 
act on multiple targets. Hence, we studied the antioxidant activity 
of the deferasirox conjugates, the stability of their iron(III) 
complexes, and the ability to inhibit metal induced αSyn 
aggregation.  We also evaluated the cytotoxicity of 1 and 2 in vitro 
and their effects in NPC cell models. Deferasirox (3) was also 
investigated for comparative purposes. The chemical and 
biological properties of the conjugates confirm that the 
conjugation with the CyD cavity represents a promising strategy 
to design new non-toxic multifunctional molecules. 
 
 
Figure 1. Chemical structure of the derivatives in this study. 
Results and Discussion 
Synthesis and Characterization 
Considering the pharmacological properties of 3 and the ability of 
CyDs to act as carriers, antiaggregants, and neuroprotective 
agents, we envisaged a simple reaction via the carboxylic group 
of 3 to obtain novel CyD conjugates. Amide condensation was 
thus performed between 3 and 6A-amino-6A-deoxy-β-cyclodextrin 
or 3A-amino-3A-deoxy-2A(S),3A(S)-β-cyclodextrin in the presence 
of suitable activating agents to obtain the 6-monofunctionalized 1 
and the 3-monofunctionalized 2 isomers, respectively.  
Such conjugation was confirmed by mass spectrometry (MS). 
ESI-MS spectra of the conjugates 2 and 1 show two peaks 
resulting from singly charged (m/z 1511.4 [P+Na]+) and doubly 
charged ions (m/z 764.2 [P+H+K]2+). 6-Functionalized and 3-
functionalized derivatives have significant differences due to the 
different synthetic routes followed to obtain the amino-CyD used 
in the amide condensation reaction. Because of a chair flip of the 
modified altrose unit in the 3-functionalized CyD derivatives, the 
cavity is elliptically distorted, whereas the functionalization at the 
6-position does not dramatically influence the CyD cavity 
according to the literature.22,23 Thus, the kind of functionalization 
strategy used to obtain the CyD conjugates may confer different 
properties to the resulting conjugates.24 
The new compounds were further characterized by 1H and 13C 
NMR spectroscopy. The 1D spectra of the products were 
assigned using 2D experiments (COSY, TOCSY, HSQC, HMBC, 
and ROESY, Figures S1-S6). The NMR spectra of 1 and 2 further 
confirm ligand conjugation as they display signals due to the 3 
and CyD moieties, the former resonating in the aromatic region.  
Other diagnostic signals of these CyD conjugates include those 
of the carbonyl groups at δ=166.0 and 165.4 ppm in the 13C 
spectrum of 1 and 2, respectively. 
As for 1, chemical shifts corresponding to H-1 protons (Hs-1) 
of the CyD moiety are divided into four groups (Figure 2) upon the 
functionalization that made them inequivalent. Moreover, H-6 
protons (Hs-6) of the CyDs are spread as a consequence of the 
presence of the aromatic moiety linked to the CyD rim. In 
particular, the H-6A protons appear at δ= 4.05 and 3.04 ppm 
because of the aromatic ring current effect as reported for other 
aromatic CyD derivatives.25  
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Figure 2. 1H NMR spectra of 1 (top) and 2 (bottom) in D2O at 500 MHz.. 
 
 
 
Figure 3. ROESY spectrum of 1 in D2O at 500 MHz. 
 
 
The analysis of the ROESY spectrum (Figure 3) reveals the 
presence of through-space proximities between an aromatic ring 
of the 3 moiety and Hs-3, Hs-5 of the CyD. Since these protons 
of the CyD are pointed towards the interior of the cavity, the 
formation of an inclusion complex of the pendant with the CyD 
cavity can be hypothesized. In particular, intense cross peaks 
were detected between H-13, H-14, H-15, and H-16 of the 
aromatic ring a and Hs-3 and Hs-5 of the CyD. ROESY data 
suggest that the phenolic ring a is inside the CyD cavity. 
 
Moreover, the NMR spectrum did not change with the increase of 
the concentration of 1 suggesting the intramolecular interaction 
and, therefore, the self-inclusion of the pendant. This compound 
was also characterized by CD spectroscopy in order to further 
investigate the interaction of the 3 moiety with the β-CyD cavity. 
The CD spectrum, at pH 6.8, of 1 shows two positive bands at 211 
and 315 nm and two more intense negative bands at 233 nm and 
275 nm. These bands are in the absorption region of the aromatic 
rings and are due to the dipole-dipole coupling between the 3 
moiety and the β-CyD cavity. This behavior has been generally 
reported for functionalized CyDs, and it is due to the interaction of 
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the functionalizing moiety26 with the CyD. Furthermore, the CD 
spectrum is strongly influenced by the presence of 1-adamantanol 
(ADM), a well-known high-affinity guest of CyD cavity, in keeping 
with the self-inclusion (Figures 4 and S7). The intensity and 
absorption maximum wavelength of the band's changes with 
increasing concentrations of ADM suggesting a modification of 
the orientation of the aromatic pendant concerning the CyD cavity. 
 
Figure 4. CD spectra of 1 (50 μM) in the presence of increasing concentrations 
of ADM (50-500 μM). 
Analogously to 1, the self-inclusion of the aromatic ring a can be 
proposed for the 3-functionalized conjugate by NMR and CD data. 
The 1H NMR spectrum of 2 shows that the functionalization splits 
out the H-1 protons of the CyD into five groups (Figure 2). In 
particular, H-1A of the functionalized sugar of the CyD resonates 
at 4.58 ppm. The synthetic strategy followed to functionalize CyDs 
at the 3-hydroxyl group leads to configuration inversions of C-2 
and C-3 and an altrose unit (ring A) replaces a glucose unit in the 
CyD molecule (Figure S8). As a consequence, H-2A and H-3A 
are strongly shifted downfield at 4.30 ppm as typically observed 
for other 3-functionalized derivatives.19 ROESY spectra display 
intense NOE-correlation peaks between aromatic protons and 
inner CyD protons suggesting the inclusion of ring a (Figures S9 
and S10). 
Finally, further evidence of the self-inclusion of the pendant is 
provided by CD experiments (Figure 5) in the presence of ADM. 
CD spectra of 2 show intense dichroic bands at 222, 233, 275 and 
315 nm. These bands are associated with the π- π* absorption 
bands of the aromatic moiety. The differences in CD spectra of 1 
and 2 can be anticipated according to the empirical rules that 
interpret the induced circular dichroism observed for a 
chromophore inside or outside of the CyD cavity.26 1 and 2 are 
structural isomers, and the rim of 2 is quite distorted owing to the 
presence of the altrose ring. For this reason, a different orientation 
of the 3 moiety in 1 and 2 can explain the different CD spectra. 
The reduction in the intensity of the dichroic bands of 2 with 
increasing concentrations of ADM reveals the displacement of the 
included aromatic ring from the CyD cavity (Figure 5). 
 
 
Figure 5. CD spectra of 2 (50 μM) in the presence of increasing concentrations 
of ADM (50 μM-5 mM). 
Proton and iron(III) complex stability constants 
Ligand 3 possesses a 1,2,4-triazole framework substituted by two 
phenolic substituents in position 3 and 5 and a benzoic acid 
moiety in position 1. The values of proton/iron(III) stability 
constants were determined by spectrophotometric titrations 
(Figures S11-S19) and are reported in Tables 1 and 2. 
For protonation stability constants (Table 1), pKa-carboxy 
corresponds to the deprotonation of the carboxylic group, 
whereas the values of pKa-phenol1 and pKa-phenol2 are characteristic 
of the deprotonation of the phenolic groups. The values 
determined in this study are consistent with the values reported 
elsewhere.27 
In comparison with 3, both CyD compounds 1 and 2 possess 
lower pKa values associated with the deprotonation of phenolic 
groups. NMR and CD data suggest the self-inclusion of the a ring 
of the CyD derivatives and this behavior could decrease the 
protonation constant of this phenol group compared to 3. A 
decrease in the values of the protonation stability constants has 
been reported in the literature for other CyD derivatives and has 
been attributed to the hydrophobic effects of the CyD cavity.12 
 
Table 1. pKa values for 3 and the two conjugates (25°C, 0.1 M KCl) in the molar 
ratio of 1:0.2 H2O/DMSO solution. Repeated measurements can result in about 
3% error. 
pKa 3 1 2 
pKa-carboxy 4.8 - - 
pKa-phenol1 10.3 8.8 9.5 
pKa-phenol2 12.3 12.1 12.0 
 
 
For iron(III) stability constants, 3 is a tridentate chelating agent, 
mainly forming a 2:1 chelator/iron(III) complex at physiological 
pH.28 Our data (Table 2) confirm these results and demonstrate 
that the CyD conjugates form the FeL and FeL2 species similarly 
to 3. In particular, FeL2 is the sole complex species present at 
physiological pH for both CyD conjugates (Figures S14 and S19; 
pH 8.4 in the molar ratio of 1:0.2 H2O/DMSO solution is closely 
equivalent to pH 7.4 in the aqueous solution). However, the iron(III) 
complex stability constants values of 1 and 2 are lower than those 
of 3. This trend has been observed for other CyD derivatives and 
associated to the steric hindrance associated with the CyD 
scaffold. 
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Table 2. Overall formation constants (log βmnq) of FeIII complexes with 3 and the two 
conjugates (25 °C, 0.1 M KCl) in the molar ratio of 1:0.2 H2O/DMSO solution. 
Repeated measurements can result in about 3% error. 
log βmnq 3 1 2 
log β111 27.0 - - 
log β110 24.5 21.4 21.8 
log β121 45.3 - - 
log β120 39.3 35.3 36.0 
*pFeIII8.4 23.6 22.5 22.7 
*pFeIII8.4 were calculated under the conditions of [FeIII] total  =1 µM, 
[ligand] total=10 µM and pH=8.4. pH 8.4 in the molar ratio of 1:0.2 H2O/DMSO 
solution is closely equivalent to pH 7.4 in the aqueous solution. 
 
Antioxidant activity 
Mounting evidence suggests a pivotal role of oxidative stress in 
metal-overload diseases29 and neurodegenerative diseases30 and 
hence much effort has been undertaken to target it using new and 
powerful antioxidants.31 Antioxidants such as polyphenols, 
vitamins A and E have been proposed as therapeutic agents for 
preventing and reducing the rate of progression of 
neurodegenerative diseases.32 
To assess the antioxidant activity of the CyD derivatives, the 
Trolox equivalent antioxidant capacity (TEAC) assay was used to 
quantify it.  
The capacity of the systems to scavenge ABTS●+ at 1, 3, and 6 
minutes was compared to Trolox, an analog of vitamin E, and was 
thus expressed as TEAC values (Figure 6). The antioxidant 
activity of 1 is two times higher than Trolox and similar to that of 
3. Furthermore, it increases in a time-dependent manner; on the 
other hand, the TEAC values of 2 are slightly lower than those of 
1 and 3. These data suggest that the free radical scavenging 
capacity of the derivatives can be attributed to the high reactivity 
of the hydroxyl groups on the aromatic rings as observed for other 
analogous systems.19 In the case of 2, the hydroxyl groups may 
be less available to react with the radical cation, probably due to 
the higher rigidity of the system compared to the analogous 6-
functionalized derivative. Similar behavior has also been reported 
for related cyclodextrin-deferiprone conjugates.12 However, the 
ability of 2 to scavenge free radicals is much higher than that of 
Trolox. This suggests that the CyD conjugates could be powerful 
antioxidants with activity similar to that of several polyphenols. 
 
 
 
Figure 6. TEAC values at 1, 3, and 6 min for CyD derivatives 1, 
2, and 3. The values are expressed as the average of three 
independent assays, and error bars show standard deviations. 
 
Effect on α-synuclein aggregation 
The aggregation of proteins into toxic conformations plays a 
critical role in the development of different neurodegenerative 
disorders such as PD, Alzheimer’s diseases (AD), and dementia 
with Lewy Bodies (DLB).33  
DLB and PD are amongst a group of diseases referred to as α-
synucleinopathies that are characterized by α-synuclein (αSyn) 
accumulation in cortical and subcortical regions.34 Therefore, 
compounds that can delay and/or prevent the aggregation 
process of αSyn could lead to a new therapeutic strategy for 
treating PD and other α-synucleinopathies. The interaction of 
proteins with metals often plays a crucial role in the aggregation. 
In particular, copper(II) and iron(III) are the most effective ions in 
promoting αSyn aggregation.35  
To investigate the influence of both CyD conjugates (1 and 2) on 
αSyn aggregation, we monitored the iron and copper-induced 
fibrillation of the protein in the absence and presence of 1, 2 and 
their parent compounds (3 and βCyD) using a dynamic light 
scattering (DLS) technique. The effect of 3 on the metal-induced 
αSyn aggregation was not determined because of the 
precipitation of its metal complexes in the assay conditions. 
The hydrodynamic diameter of αSyn (mean diameter = 6.4 ± 0.3 
nm) confirms the existence of the protein in a monomeric state in 
keeping with data reported elsewhere.36,37 Moreover, the size 
distribution of αSyn remains substantially unchanged after 24 h in 
these conditions. The presence of Fe3+ and Cu2+ promotes 
aggregate formation.  
DLS data indicate that both CD conjugates 1 and 2 efficiently 
inhibit metal-induced αSyn aggregation whereas unfunctionalized 
β-CyD was not able to suppress the aggregation. In particular, 1 
prevents αSyn aggregation at t=0 and shows only a small 
percentage of oligomers (5 %) with a mean diameter of 28 nm at 
t = 24 h (Figure S20). Analogously, 2 is efficient in suppressing 
αSyn aggregation (Figure S21). Indeed, no aggregate is 
discernible at t = 0 and t = 24 h, only the size distribution (i.e., the 
polydispersity index) of the protein increased to a small extent. 
The behavior of these derivatives could be explained by the 
correlation between the capacity of inhibiting metal-induced 
aggregation and their metal-binding ability. As described above, 
1, 2, and 3 form a 2:1 chelator/iron complex at physiological pH 
with high stability constant.27,28 3 also has a moderate affinity for 
Cu2+ as demonstrated by the value of 18.8 for log β (CuL), and 
23.9 for log β2 (CuL2) reported elsewhere.38 As observed for iron, 
we anticipate the conjugation with CyD does not significantly 
modify the copper-binding ability of the chelators.12,31 Moreover, 
we confirmed through UV-vis and CD spectroscopy that both 
derivatives maintain the ability of 3 to complex copper ions. In 
particular, the absorption and CD bands of both CyD conjugates 
dramatically change upon addition of Cu2+ ions indicating the 
copper complexation (Figure S22). Overall, these systems can be 
used to gain control of iron and copper toxicity that is strictly 
implicated in protein aggregation. 
 
Effect on Niemann-Pick disease type C (NPC) Cells 
Since CyDs are applied in NPC, and other neurodegenerative 
disorders and CyD treatment has been shown to be beneficial and 
well-tolerated in NPC cells, we tested 3 and its CyD conjugates (1 
and 2) in NPC cells in comparison with HP-B-CD. For 
completeness, we also evaluated the known compound 4 (a dual 
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action CyD-Cu chelator)12 and the clioquinol-like CyD analog 5 
(Figure S23) that belong to a class of CyDs conjugates formerly 
proposed by us as multifunctional antineurodegenerative agents. 
A dose-response study was performed on Npc1+/+ (wild type) 
CHO cells using 72 hours of treatment to determine the 
cytotoxicity profiles. CyD compounds did not have any detrimental 
effects in terms of cell viability and did not affect relative lysosomal 
volume in the concentrations range tested (Figure 7). The 
conjugation with CyD significantly reduced the cytotoxicity of 
these compounds as observed in the case of other CyD 
conjugates.39 However, treatment with 3 over 72 hours 
significantly reduced viability at all doses tested, compared to the 
untreated group and CyD treated cells in a dose-dependent 
dependent manner (Figure 7A). Also, 3 increased the acidic 
compartment volume of Npc1+/+ CHO cells at low concentrations 
(55% at 50 μM, 35% at 100 μM) in WT cells, while decreasing total 
acidic compartment volume at high concentrations (39% at 250 
μM, 69% at 500 μM) (Figure 7B).  
These compounds were then tested on NPC1 deficient CHO cells. 
Npc1-/- cells showed substantial increase in relative lysosomal 
volume (32%) compared to Npc1+/+ cells (p<0.0001) (Figure 7C). 
Total acidic compartment volume decreased with 4 by 21.5% 
(p<0.0001-normalised to Npc1+/+ levels with p 0.0539), with 1 by 
23.5% (p<0.0001), 2 by 20.3% (p<0.0001), 5 by 12.3% (p<0.001), 
HPBCyD by 30% (p<0.0001-normalised to Npc1+/+ levels p value 
0.9995) and 3 by 23.5% (p<0.0001 normalised to Npc1+/+ levels 
with p 0.0534) (Figure 7C). 
A toxicity study (Table 3) in HepG2 (immortalized human liver 
carcinoma cells) was carried out. This confirmed that the CyD-
deferasirox conjugates 1, 2 are substantially less toxic (or less 
antiproliferative) in cells than deferasirox alone (Figure S24). 
Solubility studies established that 1-3 had good solubility (>100 
µM (Table S1). 
 
Table 3. HepG2 toxicity study. 
Compound IC50 (μM)a 
1 >100 
2 >100 
3 0.98b 
a  (average of 3 replicates). b estimated. 
 
Figure 7. Effect of CyDs on NPC cells. 
 
Conclusions 
Two novel CyD-conjugated deferasirox analogs, 1 and 2, have 
been synthesized and thoroughly investigated. The derivatives 
have significant in vitro antioxidant capacity and can complex 
metal ions with high stability constants. Therefore, they can 
completely inhibit metal-induced protein aggregation and the 
formation of amyloid fibrils. These features of 1 and 2 are highly  
 
 
 
 
 
 
 
 
 
desirable considering the critical involvement of metal ions in 
protein misfolding and aggregation, which are hallmarks of 
several neurodegenerative disorders. 
Furthermore, the cyclodextrin moiety renders these systems less 
toxic than deferasirox, well-known for the side effects when 
administrated in iron-overload diseases. Most important 
advantages of both 1 and 2 are their good solubility in water and 
the possibility of forming inclusion complexes to include 
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endogenous compounds, such as cholesterol, correcting 
lysosomal volume in NPC cells. Compared to the other CyD 
conjugates previously studied by us,12,13 1 and 2 represent the 
first example of non toxic conjugates of a drug on the market that 
we have studied in a model of Childhood Alzheimer’s (NPC). 
Overall, the conjugates hold promise as multitargeted therapies 
in the treatment of disorders of metal dyshomeostasis and lipid 
imbalances. 
Experimental Section 
Chemicals 
6A-Amino-6A-deoxy-β-cyclodextrin was synthesized by a microwave-
assisted procedure starting from the corresponding 6-tosylate derivative 
as reported elsewhere40, whereas 3A-amino-3A-deoxy-2A(S),3A(S)-β-
cyclodextrin was obtained from TCI. Starting materials were purchased 
from Molekula, UK or Cyclolab, Hungary, and human αSyn was purchased 
from Sigma–Aldrich. Cu2+ stock solutions were prepared by dissolving the 
corresponding perchlorate in water and titrating the resulting solutions with 
standardized EDTA by using murexide. Ferric ion solutions were prepared 
by dissolving FeCl3·6H2O in 0.01 M hydrochloric acid to prevent hydrolysis. 
Iron solution titer was spectrophotometrically determined on the Fe–
desferal complex at 428 nm. For clarity, the sugar units in β-CyD 
derivatives are labeled A–G counter-clockwise starting from the modified 
ring (denoted as A) and viewing from the upper rim (Figure S25). 
Synthesis of 4-[3,5bis(2‐hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-N-[6A-
amino-6A-deoxy-β-cyclodextrin] benzamide (1) 
HOBt (24 mg, 0.175 mmol), DCC (36 mg, 0.175 mmol) and triethylamine 
(50 μL, 0.53 mmol) were added to a solution of 3 (65.5 mg, 0.175 mmol) 
in dry DMF (5 mL). After 20 min, 6A-amino-6A-deoxy-β-cyclodextrin (205 
mg, 0.175 mmol) was added. The reaction was stirred at room temperature 
under argon for 48 h. The solvent was evaporated to dryness in vacuo. 
The crude product was then triturated with diethyl ether (3 × 3 mL), 
followed by an acetone trituration cold (3 × 4 mL) and hot acetone 
trituration (3 × 3 mL) and the crude solids were purified by reverse phase 
chromatography using a 30g  Biotage  KP-RC-18 column (eluent: 
H2O→CH3OH) to give the title product (white solid). For numbering of 1 
refer to Figure 1. Yield: 64 % (168 mg, 0.11 mmol); TLC: Rf=0.28 
(iPrOH/AcOEt/H2O/NH3 4:3:2:1); 1H NMR (500 MHz, D2O): δ 7.95 (d, 
J13,14 = 7.7 Hz, 1H, H-13), 7.48 (t, J = 7.8 Hz, 1H, H-15), 7.39 (m, 1H, H-
21), 7.31 (d, J8,7 = J10,11 = 8.0 Hz, 2H, H-8 and H-10), 7.26 (d, J23,22 = 7.5 
Hz, 1H, H-23), 7.09 (d, J16,15 = 8.2 Hz, 1H, H-16), 7.04 (m, 4H, H-7, H-11, 
H-14 and H-22), 6.79 (d, J20,21 = 7.8 Hz, 1H, H-20), 5.02 (d, J1G,2G = 3.6 
Hz, 1H, H-1G of CyD), 4.96 (d, J = 3.5 Hz, 3H, Hs-1 of CyD), 4.92 (d, J = 
3.6 Hz, 1H, H-1A of CyD), 4.82 (d, J = 3.6 Hz, 2H, Hs-1 of CyD), 4.05 (d, 
J6A,6A‘ = 13.7 Hz, 1H, H-6A of CyD), 4.01 – 3.16 (m, 39H, Hs-2, Hs-3, Hs-
4 and Hs-5 of CyD), 3.16 – 2.96 ppm (m, 2H, H-6A and H-6X of CyD). 13C 
NMR (126 MHz, D2O): δ 166.0 (C=O), 160.6 (C-3), 155.9 (C-17), 154.9 
(C-19), 152.5 (C-5), 139.8 (C-6), 133.1 (C-21), 133.4 (C-9), 131.9 (C-15), 
130.7 (C-23), 127.8 (C-8, C-10), 126.9 (C-13), 122.1 (C-7 and C-11), 120.0 
(C-22 and C-14), 116.8 (C-16), 116.4 (C-20), 112.9 (C-12 and C-18), 102.3 
(C-1G of CyD), 101.8 (Cs-1 of CyD), 101.4 (C-1A of CyD), 84.0 (C-4A of 
CyD), 80.3 (Cs-4 of CyD), 73.1-71.6 (Cs-2, Cs-3 and Cs-5 of CyD), 59.6 
(Cs-6 of CyD), 41.1 ppm (C-6A of CyD). CD (H2O) λ/nm (Δε): 211 (+1.4), 
233 (-3.6), 275 (-1.7), 315 (+0.6). ESI-MS: m/z=1490.45 [M+H]+. Analytical 
8 minute Run. H2O: Acetonitrile (95: 5 to 5: 95). RT = 2.59 minutes; purity 
= 100%. (Figure S26-28) 
Synthesis of  4‐[3,5‐bis(2‐hydroxyphenyl)‐1H‐1,2,4‐triazol‐1‐yl]‐N‐[3A-
deoxy-3A-amino-β-cyclodextrin] benzamide (2) 
HOBt (24 mg, 0.175 mmol), DCC (36 mg, 0.175 mmol) were added to a 
solution of 3 (65.5 mg, 0.175 mmol) in dry DMF (5 mL). After 20 min, 3A-
amino-3A-deoxy-β-cyclodextrin (199 mg, 0.175 mmol) was added. 
Reaction was stirred at room temperature under argon for 48 h. The 
solvent was evaporated to dryness in vacuo. The crude product was then 
triturated with diethyl ether (3 × 3 mL), followed by an acetone trituration 
cold (3 × 4 mL) and hot acetone trituration (3 × 3 mL) and the crude solids 
were purified by reverse phase chromatography using a 30g  Biotage  KP-
RC-18 column (eluent: H2O→CH3OH) to give the entitled product (white 
solid). For numbering of 2 refers to Figure 1. Yield: 57 % (149 mg, 0.10 
mmol); TLC: Rf = 0.43 (iPrOH/AcOEt/H2O/NH3 4:3:2:1); 1H NMR (500 
MHz, D2O): δ 7.94 (d, J = 7.7 Hz, 1H, H-13), 7.80 (bs, 2H, H-8 and H-10), 
7.64–7.26 (m, 5H, H-7, H-11, H-15, H-21 and H-23), 7.14–6.95 (m, 3H, H-
14, H-16 and H-22), 6.71 (s, 1H, H-20), 5.09 – 4.99 (m, 2H, Hs-1 of CyD), 
4.97 (d, J = 3.4 Hz, 1H, H-1 of CyD), 4.85 (s, 2H, Hs-1 of CyD), 4.81 (s, 
1H, H-1 of CyD), 4.59 (bs, 1H, H-1A of CyD), 4.46 – 2.78 (m, 42H, Hs-2, 
Hs-3, Hs-4, Hs-5 and Hs-6 of CyD).13C NMR (126 MHz, d6-DMSO):  δ  
165.4 (C=O), 160.2 (C-3), 156.8 (C-17), 155.7 (C-19), 152.4 (C-5), 140.2 
(C-6),  134.6 (C-9), 132.9 (C-21), 131.8 (C-15), 131.4 (C-23), 128.8 (C-8, 
C-10), 127.1 (C-13), 123.6 (C-7 and C-11), 120.0 (C-22 and C-14), 117.5 
(C-16), 116.6 (C-20), 114.9 (C-12), 114.1 (C-18), 104.6 (C-1A of CyD), 
102.4-102.0 (Cs-1 of CyD), 82.4-81.0 (Cs-4 of CyD), 79.9 (C-5A of CyD), 
73.6-71.2 (Cs-2, Cs-3 and Cs-5 of CyD), 60.7-60.0 (Cs-6 of CyD), 51.7 (C-
3A). ESI-MS: m/z= 764.2 [P+H+K]2+, 1490.45 [M+H]; CD (H2O) λ/nm (Δε): 
222 (+ 9.4), 233 (-10.2), 275 (-11.2), 315 (+4.5).  Analytical 8 minute Run. 
H2O: Acetonitrile (95: 5 to 5: 95).  RT = 2.45 minutes; purity = 99%. 
Synthesis of 6A‐deoxy‐6A‐[{(5-bromo-8‐hydroxyquinolyl)‐2‐
carboxyl}amino]‐β‐cyclodextrin (5) 
HOBt (22 mg, 0.16 mmol), DCC (33 mg, 0.16 mmol) and 5-bromo-8-
hydroxyquinoline-2-carboxylic acid (Scheme S1) (43 mg, 0.16 mmol) were 
dissolved in anhydrous DMF (4.0 ml) under inert conditions. To this 
solution NEt3 (45 µL, 0.32 mmol) was added followed by 6-monodeoxy-6-
monoamino-β-cyclodextrin (187 mg, 0.16 mmol) added portion wise over 
30 minutes at room temperature with vigorous stirring. The reaction 
mixture was stirred overnight under nitrogen. After 12 hours further 
addition of DCC (33 mg, 0.16 mmol), HOBt (22 mg, 0.16 mmol) and NEt3 
(22.5 µL, 1.0 eq) and heated at 50 oC for 5 days. Upon completion the 
reaction mixture was concentrated to dryness before trituration of the 
crude solid using diethyl ether (3 x 5 ml) was undertaken. The ether was 
decanted and the resulting solid was triturated using hot acetone (6 x 6 ml) 
and the solid product was dried by desiccation. The material was purified 
using reverse phase chromatography (30 g C18 Biotage Column) using 
liquid loading in H2O: DMSO (1:2, 5 ml). The purification was run using a 
solvent system of H2O: MeOH (100:0 – 0:100) yielding the pure final 
product 5 (124 mg, 56% yield, Rf = 0.5 (AcOEt: IPA: H2O: NH3 aq. (4: 3: 
2: 1)). Analytical 8 minute run. H2O: acetonitrile (70: 30 to 5: 95); RT = 
1.84 minutes; purity = 100%. 1H NMR (600 MHz, DMSO-d6) δ 10.22 (s, 
1H, NH), 9.53 (dd, J = 7.5, 4.4 Hz, 1H, OH of HQ), 8.57 (d, J = 8.7 Hz, 1H, 
H-3 of HQ), 8.24 (d, J = 8.7 Hz, 1H, H-4 of HQ), 7.86 (d, J = 8.3 Hz, 1H, 
H-6 of HQ), 7.10 (d, J = 8.3 Hz, 1H, H-7 of HQ), 5.94 (d, J = 6.0 Hz, 1H, 
OH of CyD), 5.86 (dd, J = 16.6, 6.4 Hz, 2H, OH of CyD), 5.75 (d, J = 11.4 
Hz, 3H, OH of CyD), 5.72 – 5.65 (m, 6H, OH of CyD), 5.63 (s, 1H, OH of 
CyD), 5.51 (d, J = 7.5 Hz, 1H, OH of CyD), 4.98 (d, J = 3.7 Hz, 1H, H-1 of 
CyD), 4.84 (m, 3H, H-1 of CyD), 4.81 (d, J = 3.5 Hz, 1H, H-1 of CyD), 4.76 
(d, J = 3.6 Hz, 1H, H-1 of CyD), 4.65 (d, J = 3.5 Hz, 1H, H-1 of CyD), 4.53 
(s, 1H), 4.50 (s, 1H), 4.45 (s, 2H), 4.25 (s, 1H), 4.00 – 3.94 (m, 1H), 3.86 
(dd, J = 12.3, 4.1 Hz, 1H), 3.81 (d, J = 11.2 Hz, 1H), 3.72 (d, J = 13.2 Hz, 
1H), 3.69 (s, 1H), 3.72 – 3.66 (m, 1H), 3.68 – 3.60 (m, 8H), 3.63 – 3.59 (m, 
2H), 3.57 (d, J = 11.4 Hz, 2H), 3.56 – 3.49 (m, 4H), 3.42 – 3.33 (m, 8H), 
3.17 (t, J = 5.9 Hz, 1H), 2.56 – 2.50 (m, 1H). 13C NMR (151 MHz, DMSO-
d6) δ (ppm): 163.4 (C=O), 154.4 (C-8 of HQ), 148.6 (C-2 of HQ), 137.6 (C-
4 of HQ), 137.2 (C-9 of HQ), 133.1 (C-6 of HQ), 128.4 (C-10 of HQ), 120.8 
(C-3 of HQ), 113.0 (C-7 of HQ), 108.7 (C-5 of HQ), 102.7 (C-1 of CyD), 
102.7(C-1 of CyD), 102.6 (C-1 of CyD), 102.3 (C-1 of CyD), 102.1 (C-1 of 
CyD), 101.5 (C-1 of CyD), 85.03 (C-4A of CyD), 82.3-80.9 (Cs-4 of CyD), 
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74.2-70.5 (Cs-3, Cs-5, Cs-2 of CyD), 60.5 (C-6 of CyD), 60.3 (C-6 of CyD), 
60.2 (C-6 of CyD), 60.1 (C-6 of CyD), 59.6 (C-6 of CyD), 58.9 (C-6 of CyD), 
40.6 (C-6A of CyD). HRMS: m/z= 1405.3227 [M+Na]+. Analytical 8 minute 
run; H2O: acetonitrile (70: 30 to 5: 95); RT = 1.84 minutes; purity =100%. 
NMR spectroscopy and MS spectrometry 
1H and 13C NMR spectra were recorded at 25 °C with a Varian UNITY 
PLUS‐500 spectrometer at 499.9 and 126 MHz, respectively. The NMR 
spectra were obtained by using standard pulse programs from the Varian 
library. The 2D experiments (COSY, TOCSY, gHSQCAD, gHMBC, 
ROESY) were acquired by using 1000 data points, 256 increments, and a 
relaxation delay of 1.2 s. The spectra were referred to as the solvent signal. 
UV-visible and circular dichroism spectroscopy 
UV spectra were recorded on an Agilent 8452A diode array 
spectrophotometer. Circular dichroism measurements were performed on 
a JASCO spectropolarimeter (model J-1500).  
Iron stability constants determination 
The automated titration system consists of a Metrohm Dosimat 765 liter ml 
syringe, a Mettler Toledo MP230 pH meter with SENTEK pH electrode 
(P11), and an HP 8453 UV-visible spectrophotometer with a Hellem quartz 
flow cuvette being circulated through by a Gilson Mini-plus #3 pump — 
speed capability (20 mL/min). A potassium chloride electrolyte solution 
(0.1 mol/L) was used to maintain the ionic strength. The temperature of the 
test solutions was maintained in a thermostatic jacketed titration vessel at 
25 °C (± 0.1 °C) using a Fisherbrand Isotemp water bath. The pH 
electrodes were calibrated using GLEE41 with data obtained by titrating a 
volumetric standard HCl (0.1 mol/L) in KCl (0.1 mol/L) with KOH (0.1 mol/L) 
under an argon gas atmosphere in the vessel. The solution under 
investigation was stirred vigorously during the experiment. For pKa 
determinations, a cuvette path length of 10 mm was used while for metal 
stability constant determinations, a cuvette path length of 50 mm was used. 
All instruments were interfaced to a computer and controlled by an in-
house program. An automated titration adopted the following strategy: the 
pH of a solution was increased by 0.1 pH unit by the addition of potassium 
hydroxide solution (0.1 mol/L) from the autoburette. The pH readings were 
judged to be stable if their values varied by less than 0.01 pH unit after a 
set incubation period. For pKa determinations, an incubation period of 1.5 
mins was adopted; for metal stability, constant determinations, an 
incubation period of 3 mins was adopted. The cycle was repeated until the 
defined end point pH value was achieved. Titrations were carried out in the 
solution with a molar ratio of DMSO: H2O being 0.2: 1 due to the solubility 
issue of the three analogs and/or corresponding iron-complexes. Under 
this condition, the pH meter readings are shifted, compared to the aqueous 
solution. All the titration data were analyzed with the HypSpec2014 
program42,43 (http://www.hyperquad.co.uk/). The speciation plot was 
calculated with the HYSS program.44 Analytical grade reagent materials 
were used in the preparation of all solutions.  
Dynamic light scattering measurements  
Dynamic light-scattering (DLS) measurements were carried out using a 
Zetasizer Nano ZS (Malvern Instruments, UK) equipped for backscattering 
at 173° with a 633 nm He–Ne laser. Each DLS measurement was run 
using automated, optimal measurement times, and laser attenuation 
settings according to literature.31  
Trolox Equivalent Antioxidant Capacity Assay 
In vitro, antioxidant assays were performed by 2,2’-azinobis(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS●+) radical 
cation decolorization assay using 6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid (Trolox) as reported elsewhere.45 In brief, the radical 
cation ABTS+˙ was generated by a reaction between ABTS (7 mM) and 
persulphate (2.45 mM) in water for 16 h (dark, room temperature). This 
radical solution was diluted in phosphate buffer (10 mM, pH 7.4) and 
combined with different concentrations of the sample antioxidants (1, 2 and 
3). All samples were diluted approximately to provide 20–80% inhibition of 
the blank absorbance. The absorbance values were measured for 6 min. 
Solution absorbance was plotted vs. test compound concentration; each 
resultant slope was normalized concerning that obtained for Trolox to give 
the Trolox-equivalence (TEAC) value for each time point (1, 3, 6 min). All 
measurements were performed in triplicate. 
Anti-aggregation assay. 
αSyn solutions (0.5 mg/mL) were buffered at pH 6.6 and 7.4 (MOPS, 20 
mM). Iron and copper-mediated aggregation of αSyn was studied using 
suitable FeCl3 and Cu(ClO4)2 solutions in order to have a final 
concentration of 265 μM in cuvette as reported elsewhere. CyD derivatives 
were added in an equimolar amount to the copper ions.31 Each DLS 
measurement was run by using automated, optimal measurement times, 
and laser attenuation settings.  
Cell Lines 
WT and Npc1-/- null CHO cells were used (Isolation of NPC1-Deficient 
Chinese Hamster Ovary Cell Mutants by Gene Trap Mutagenesis.46 
LysoTracker Green and Propium Iodide staining 
In vitro FACs experiment were done in order to measure the acidic 
compartment volumes according to the published method.47 Live cells 
were stained with LysoTracker™ Green DND-26 (Thermo Fisher-L7526) 
at 250 nM for 10 min in PBS at RT, centrifuged at 1200x, 10 min and cells 
resuspended in FACs buffer (PBS, 1% BSA, 0.1% NaN3 sodium azide). 
Cells were stained with Propidium Iodide (20 nM) (Invitrogen-P3566) 
immediately before analysis on the FACs machine for dead cell separation. 
FACs analyses were performed with 10.000-recorded cells by using FACs 
Canto with BD software. 
Acknowledgments  
We thank Professor Robert Hider (Kings College) for useful 
discussions and help with the iron measurements. The Niemann 
Pick Research Foundation are thanked for continued financial 
support (JMG, EK, AM, FMP, JS). The authors are also grateful 
for support from Università degli Studi di Catania (Piano della 
Ricerca di Ateneo 2016-2018) and the Italian Ministero 
dell’Università e della Ricerca (VO, GV). FMP is a Wellcome Trust 
Investigator in Science. 
Keywords: deferasirox • Niemann-Pick • Iron complexes • 
protein aggregation • antioxidant 
[1] P. Delangle, E. Mintz, Dalton Trans. 2012, 41, 6359-6370. 
[2] T. Zhou, Y. Ma, X. Kong, R. C. Hider, Dalton Trans. 2012, 41, 6371-6389. 
[3] M. G. Savelieff, G. Nam, J. Kang, H. J. Lee, M. Lee, M. H. Lim, Chem. Rev. 
2019, 119, 1221–1322. 
[4] R. J. Ward, D. T. Dexter, R. Crichton, Curr. Med. Chem. 2012, 19, 2760-
2772. 
[5] J. J. Meerpohl, G. Antes, G. Rücker, N. Fleeman, E. Motschall, C. M. 
Niemeyer, D. Bassler, Cochrane Database Syst. Rev. 2012, 2. 
FULL PAPER    
 
 
 
 
 
[6] M. A. Santos, S. M. Marques, S. Chaves, Coord. Chem. Rev. 2012, 256, 
240-259. 
[7] V. M. Nurchi, G. Crisponi, J. I. Lachowicz, S. Medici, M. Peana, M. A. 
Zoroddu, J. Trace Elem. Med. Biol. 2016, 38, 10-18.  
[8] M. Marano, G. Bottaro, B. Goffredo, F. Stoppa, M. Pisani, A. M. Marinaro, F. 
S. Falvella, Eur. J. Clin. Pharm. 2016, 72, 247. 
[9] J. D. Díaz-García, A. Gallegos-Villalobos, L. Gonzalez-Espinoza, M. D. 
Sanchez-Nino, J. Villarrubia, A. Ortiz, Nat. Rev. Nephr. 2014, 10, 574. 
[10] P. Rouge, M. Becuwe, A. Dassonville-Klimpt, S. Da Nascimento, J. F. 
Raimbert, D. Cailleu, P. Sonnet, Tetrahedron 2011, 67, 2916-2924. 
[11] P. M. Dandagi, S. L. Adavi, S. Rath, A. P.  Gadad, Int. J. Pharm. Sci. 
2014, 6, suppl. 2, 251-256. 
[12] A. Puglisi, J. Spencer, V. Oliveri, G. Vecchio, X. Kong, J. Clarke, J. Milton, 
Dalton Trans. 2012, 41, 2877-2883. 
[13] V. Oliveri, F. Attanasio, A. Puglisi, J. Spencer, C. Sgarlata, G. Vecchio, 
Chem.– Eur. J. 2014, 20, 8954-8964. 
[14] V. Oliveri, A. Puglisi, M. Viale, C. Aiello, C. Sgarlata, G. Vecchio, J. 
Clarke, J. Milton and J. Spencer, Chem.-Eur. J. 2013 19 13946–13955. 
[15] V. Oliveri, F. Bellia, G. Vecchio, Chem.-Eur. J. 2017, 23, 4442-4449. 
[16] T. Serno, R. Geidobler, G. Winter, Adv. Drug Deliv. Rev. 2011, 63, 1086-
1106. 
[17]  V. Oliveri, G. Vecchio, Chem.–Asian J. 2016, 11, 1648-1657. 
[18] P. Bar-On, E. Rockenstein, A. Adame, G. Ho, M. Hashimoto, E. Masliah, J. 
Neurochem. 2006, 98, 1032-1045. 
[19] S. Kaewprasert, M. Okada, Y. Aoyama, J. Nutr Biochem. 2002, 13, 219-
225. 
[20] E. Barone, F. Di Domenico, D. A. Butterfield, Biochem. Pharmacol. 2014, 
88, 605-616. 
[21] C. Coisne,  S. Tilloy, E. Monflier, D. Wils, L. Fenart, F. Gosselet, Molecules 
2016, 21, 1748-1770. 
[22] A. Schlatter, W. D. Woggon, Adv. Synth. Catal. 2008, 350, 995-1000. 
[23] C. M. Pedersen and M. Bols, in Organic Synthesis and Molecular 
Engineering, John Wiley & Sons, Inc., Hoboken, NJ, USA, 2013, pp. 305–332. 
[24] V. Oliveri, A. Pietropaolo, C. Sgarlata, G. Vecchio, Chem.–Asian J. 2017, 
12, 110-115. 
[25] V. Oliveri, F. Bellia, A. Pietropaolo, G. Vecchio, Chem.-Eur. J. 2015, 21, 
14047-14059. 
[26] M. Kodaka, J. Phys. Chem. 1991, 95, 2110-2112. 
[27] S. Steinhauser, U. Heinz, M. Bartholomä, T. Weyhermüller, H. Nick, K. 
Hegetschweiler, Eur. J. Inorg. Chem. 2004, 4177-4192. 
[28] U. Heinz, K. Hegetschweiler, P. Acklin, B. Faller, R. Lattmann, H. P. 
Schnebli, Angew. Chemie Int. Ed. 1999, 38, 2568-2570. 
[29] K. Jomova, M.Valko, Curr. Pharm. Des. 2011, 17, 3460-3473. 
[30] E. Niedzielska, I. Smaga, M. Gawlik, A. Moniczewski, P. Stankowicz, J. 
Pera, M. Filip, Mol. Neurobiol. 2015, 1-32. 
[31] S. Ojha, H. Javed, S. Azimullah, M. E. Haque, Mol. Cell. Biochem. 2016, 
418, 59-70. 
[32] J. J. Sutachan, Z. Casas, S. L. Albarracin, B. R. Stab, I. Samudio, J. 
Gonzalez, G. E. Barreto, Nutr. Neurosci. 2012, 15, 120-126. 
[33] A. Aguzzi, T. O'Connor, Nat. Rev. Drug Discov. 2010, 9, 237-248. 
[34] E. A. Waxman, B. I. Giasson, Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 
2009, 1792, 616-624. 
[35] V. Oliveri, Eur. J. Med. Chem. 2019, 167, 10-36. 
[36] A. Dusa, J. Kaylor, S. Edridge, N. Bodner, D. P. Hong, A. L. Fink, 
Biochemistry 2006, 45, 2752-2760. 
[37] V. Oliveri, C. Sgarlata, G. Vecchio, Chem.-Asian J. 2016, 11, 2436-2442. 
[38] S. Steinhauser, U. Heinz, J. Sander, K. Z. Hegetschweiler, Anorg. Allg. 
Chem. 2004, 630, 1829-1838. 
[39] V. Oliveri, S. Zimbone, M. L. Giuffrida, F. Bellia, M. F. Tomasello, G. 
Vecchio, Chem.-Eur. J. 2018, 24, 6349-6353. 
[40] A. Puglisi, J. Spencer, J. Clarke, J. Milton, J. Inclus. Phenom. Macrocyclic 
Chem. 2012, 73, 475-478. 
[41] P. Gans, B. O’Sullivan, Talanta 2000, 51, 33-37. 
[42] P. Gans, A. Sabatini, A. Vacca, Annali di chimica 1999, 89, 45-49. 
[43] P. Gans, A. Sabatini, A. Vacca, Talanta 1996, 43, 1739-1753. 
[44] L. Alderighi, P. Gans, A. Ienco, D. Peters, A. Sabatini, A. Vacca, Coord. 
Chem. Rev. 1999, 184, 311-318. 
[45] C. Sgarlata, V. Oliveri, J. Spencer, Eur. J. Inorg. Chem. 2015, 5886-5891.  
[46] K. Higaki, H. Ninomiya, Y. Sugimoto, T. Suzuki, M. Taniguchi, H. Niwa, P.G. 
Pentchev, M.T. Vanier, K. Ohno, J. Biochem. 2001, 129, 875–880.  
[47] D. Te Vruchte, A.O. Speak, K.L. Wallom, N. Al Eisa, D. A. Smith, C. J. 
Hendriksz, L. Simmons, R. H. Lachmann, A. Cousins, R. Hartung, E. 
Mengel, H. Runz, M. Beck, Y. Amraoui, J. Imrie, E. Jacklin, K. Riddick, N. 
M. Yanjanin, C. A. Wassif, A. Rolfs, F. Rimmele, N. Wright, C. Taylor, U. 
Ramaswami, T. M. Cox, C. Hastings, X. Jiang, R. Sidhu, D. S. Ory, B. Arias, 
M. Jeyakumar, D. J. Sillence, J. E. Wraith, F. D. Porter, M. Cortina-Borja, 
F. M. Platt, J. Clin. Invest. 2014, 124, 1320-1328. 
 
FULL PAPER    
 
 
 
 
 
 
Entry for the Table of Contents  
Layout 1: 
 
FULL PAPER 
We conjugated deferasirox with 
β-cyclodextrin creating hybrid 
non-toxic molecules with multiple 
biological properties. 
 
 
 Jose Miguel Gascon, Valentina 
Oliveri,* Andrew McGown, Ecem 
Kaya, Yu-Lin Chen, Carol Austin, 
Martin Walker, Frances Platt,* 
Graziella Vecchio,* and John 
Spencer * 
Page No. – Page No. 
Synthesis and Study of Novel 
Multifunctional Cyclodextrin-
Deferasirox Hybrids 
 
  
 
 
   
 
 
 
